MediciNova, Inc. (MNOV) News

MediciNova, Inc. (MNOV): $2.27

0.02 (+0.89%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MNOV to Watchlist
Sign Up

Industry: Biotech


Ranked

of 455

in industry

Filter MNOV News Items

MNOV News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest MNOV News From Around the Web

Below are the latest news stories about Medicinova Inc that investors may wish to consider to help them evaluate MNOV as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Welcome back, investor!

William White on InvestorPlace | December 13, 2021

MediciNova gains 13% after securing new U.S. patent for MN-166 and riluzole

No summary available.

Seeking Alpha | December 13, 2021

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of ALS

LA JOLLA, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers the combination of MN-166 (ibudilast) and riluzole for the treatment of amyotrophic lateral sclerosis (ALS). Once issued, the patent ma

Yahoo | December 13, 2021

MediciNova Announces MN-166 (ibudilast) Poster Presentation at the 32nd International Symposium on ALS/MND

LA JOLLA, Calif., Dec. 10, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Dr. Malath Makhay, Director, Scientific Affairs, presented the poster of MediciNovas ongoing Phase 2b/3 clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS) at the 32nd International Symposium on ALS/MND (amyotrophic lateral sclerosis/motor neurone disease) being held virtually on December 7 - 10, 2021.

Intrado Digital Media | December 10, 2021

Brokerages Expect MediciNova, Inc. (NASDAQ:MNOV) to Post -$0.11 EPS

Brokerages expect that MediciNova, Inc. (NASDAQ:MNOV) will announce earnings of ($0.11) per share for the current quarter, Zacks reports. Zero analysts have made estimates for MediciNovas earnings, with the lowest EPS estimate coming in at ($0.11) and the highest estimate coming in at ($0.10). MediciNova posted earnings of ($0.07) per share in the same quarter []

Dakota Financial News | December 2, 2021

MediciNova Inc. (NASDAQ: MNOV) Shares Might Go Down -47.88% This Year

In today’s recent session, 2.21 million shares of the MediciNova Inc. (NASDAQ:MNOV) have been traded, and its beta is 1.33. Most recently the company’s share price was $3.35, and it changed around $0.28 or 9.12% from the last close, which brings the market valuation of the company to $156.66M. MNOV at last check was trading … MediciNova Inc. (NASDAQ: MNOV) Shares Might Go Down -47.88% This Year Read More »

Marketing Sentinel | November 23, 2021

MNOV: Addition of MN-166 to PD-1 Treatment Extends Survival in Preclinical GBM Model…

By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Business Update MN-166 in Combination with PD-1 Inhibitor Extends Survival in Preclinical Model On November 22, 2021, MediciNova, Inc. (NASDAQ:MNOV) announced results from a preclinical study of MN-166 (ibudilast) in combination with a PD-1 inhibitor presented at the 26 th Annual Meeting of the Society for Neuro-Oncology (SNO).

Yahoo | November 23, 2021

MediciNova Announces New Data regarding MN-166 (ibudilast) in Glioblastoma Presented at the 26th Annual Meeting of the Society for Neuro-Oncology

LA JOLLA, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNovas research collaborator, Justin Lathia PhD, Co-Director of the Brain Tumor Research and Therapeutic Development Center of Excellence at Cleveland Clinic Lerner Research Institute, and Professor, Department of Molecular Medicine at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, presented new data regarding MN-166 (ibudilast) from a glioblastoma animal model study at the 26 th Annual Meeting of the Society for Neuro-Oncology (SNO) held November 18 - 21, 2021 in Boston.

Intrado Digital Media | November 22, 2021

We Think MediciNova (NASDAQ:MNOV) Can Easily Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Yahoo | November 15, 2021

MediciNova Announces MN-001 (tipelukast) Data regarding Lipid Metabolism in NASH/NAFLD to be Presented at The Liver Meeting® 2021, the Annual Meeting of the American Association for the Study of Liver Diseases

LA JOLLA, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova’s research collaborator Masatsune Ogura, M.D., Ph.D., Associate Professor at the Department of General Medical Science, Chiba University Graduate School of Medicine, is presenting results and findings of a study that investigated the mechanism by whi

Yahoo | November 11, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5555 seconds.